Patients with bladder cancer and FGFR3 mutations have a favourable prognosis and are more likely to benefit from anti-FGFR3 therapy compared to patients with FGFR3-overexpressing tumors13. The gene discussed is FGFR3; the disease is urinary bladder cancer.